Literature DB >> 21917895

Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells.

Michael M Lederman1, Leonard Calabrese, Nicholas T Funderburg, Brian Clagett, Kathy Medvik, Hector Bonilla, Barbara Gripshover, Robert A Salata, Alan Taege, Michelle Lisgaris, Grace A McComsey, Elizabeth Kirchner, Jane Baum, Carey Shive, Robert Asaad, Robert C Kalayjian, Scott F Sieg, Benigno Rodriguez.   

Abstract

BACKGROUND: Failure to normalize CD4(+) T-cell numbers despite effective antiretroviral therapy is an important problem in human immunodeficiency virus (HIV) infection.
METHODS: To evaluate potential determinants of immune failure in this setting, we performed a comprehensive immunophenotypic characterization of patients with immune failure despite HIV suppression, persons who experienced CD4(+) T-cell restoration with therapy, and healthy controls.
RESULTS: Profound depletion of all CD4(+) T-cell maturation subsets and depletion of naive CD8(+) T cells was found in immune failure, implying failure of T-cell production/expansion. In immune failure, both CD4(+) and CD8(+) cells were activated but only memory CD4(+) cells were cycling at increased frequency. This may be the consequence of inflammation induced by in vivo exposure to microbial products, as soluble levels of the endotoxin receptor CD14(+) and interleukin 6 were elevated in immune failure. In multivariate analyses, naive T-cell depletion, phenotypic activation (CD38(+) and HLA-DR expression), cycling of memory CD4(+) T cells, and levels of soluble CD14 (sCD14) distinguished immune failure from immune success, even when adjusted for CD4(+) T-cell nadir, age at treatment initiation, and other clinical indices.
CONCLUSIONS: Immune activation that appears related to exposure to microbial elements distinguishes immune failure from immune success in treated HIV infection.

Entities:  

Mesh:

Year:  2011        PMID: 21917895      PMCID: PMC3218674          DOI: 10.1093/infdis/jir507

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  50 in total

1.  Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment.

Authors:  Colleen F Kelley; Christina M R Kitchen; Peter W Hunt; Benigno Rodriguez; Frederick M Hecht; Mari Kitahata; Heide M Crane; James Willig; Michael Mugavero; Michael Saag; Jeffrey N Martin; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2009-03-15       Impact factor: 9.079

2.  Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.

Authors:  Wei Jiang; Michael M Lederman; Peter Hunt; Scott F Sieg; Kathryn Haley; Benigno Rodriguez; Alan Landay; Jeffrey Martin; Elizabeth Sinclair; Ava I Asher; Steven G Deeks; Daniel C Douek; Jason M Brenchley
Journal:  J Infect Dis       Date:  2009-04-15       Impact factor: 5.226

3.  Interleukin-7 receptor signaling is deficient in CD4+ T cells from HIV-infected persons and is inversely associated with aging.

Authors:  Douglas A Bazdar; Magdalena Kalinowska; Scott F Sieg
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

4.  Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.

Authors:  Robert C Kaplan; Lawrence A Kingsley; Stephen J Gange; Lorie Benning; Lisa P Jacobson; Jason Lazar; Kathryn Anastos; Phyllis C Tien; A Richey Sharrett; Howard N Hodis
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

5.  Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy.

Authors:  Giulia Marchetti; Giusi M Bellistrì; Elisa Borghi; Camilla Tincati; Stefania Ferramosca; Maria La Francesca; Giulia Morace; Andrea Gori; Antonella D'Arminio Monforte
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177

6.  Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy.

Authors:  Félix Gutiérrez; Sergio Padilla; Mar Masiá; José A Iribarren; Santiago Moreno; Pompeyo Viciana; José Hernández-Quero; Remedios Alemán; Francesc Vidal; Miguel Salavert; José R Blanco; Manuel Leal; Fernando Dronda; Santiago Perez Hoyos; Julia del Amo
Journal:  Curr HIV Res       Date:  2008-03       Impact factor: 1.581

7.  Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.

Authors:  Gregory K Robbins; John G Spritzler; Ellen S Chan; David M Asmuth; Rajesh T Gandhi; Benigno A Rodriguez; Gail Skowron; Paul R Skolnik; Robert W Shafer; Richard B Pollard
Journal:  Clin Infect Dis       Date:  2009-02-01       Impact factor: 9.079

8.  S-phase entry leads to cell death in circulating T cells from HIV-infected persons.

Authors:  Scott F Sieg; Douglas A Bazdar; Michael M Lederman
Journal:  J Leukoc Biol       Date:  2008-03-27       Impact factor: 4.962

9.  Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis.

Authors:  Nicholas Funderburg; Angel A Luciano; Wei Jiang; Benigno Rodriguez; Scott F Sieg; Michael M Lederman
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

10.  Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.

Authors:  Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton
Journal:  PLoS Med       Date:  2008-10-21       Impact factor: 11.069

View more
  162 in total

Review 1.  HIV and inflammation: mechanisms and consequences.

Authors:  Peter W Hunt
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

2.  Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation.

Authors:  Peter J Kuebler; Megha L Mehrotra; Brian I Shaw; Kaitlyn S Leadabrand; Jeffrey M Milush; Vanessa A York; Patricia Defechereux; Robert M Grant; Esper G Kallás; Douglas F Nixon
Journal:  J Infect Dis       Date:  2015-08-26       Impact factor: 5.226

3.  Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.

Authors:  Jesper F Højen; Thomas A Rasmussen; Karen Lise D Andersen; Anni A Winckelmann; Rune R Laursen; Jesper D Gunst; Holger J Møller; Mayumi Fujita; Lars Østergaard; Ole S Søgaard; Charles A Dinarello; Martin Tolstrup
Journal:  Mol Med       Date:  2015-04-14       Impact factor: 6.354

4.  Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death.

Authors:  E T Overton; D Kitch; C A Benson; P W Hunt; J H Stein; M Smurzynski; H J Ribaudo; P Tebas
Journal:  Clin Infect Dis       Date:  2013-02-05       Impact factor: 9.079

5.  Inflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease.

Authors:  Carey L Shive; Joseph C Mudd; Nicholas T Funderburg; Scott F Sieg; Benjamin Kyi; Doug A Bazdar; Davide Mangioni; Andrea Gori; Jeffrey M Jacobson; Ari D Brooks; Jeffrey Hardacre; John Ammori; Jacob D Estes; Timothy W Schacker; Benigno Rodriguez; Michael M Lederman
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

6.  Cycling memory CD4+ T cells in HIV disease have a diverse T cell receptor repertoire and a phenotype consistent with bystander activation.

Authors:  Wei Jiang; Souheil-Antoine Younes; Nicholas T Funderburg; Joseph C Mudd; Enrique Espinosa; Miles P Davenport; Denise C Babineau; Scott F Sieg; Michael M Lederman
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

Review 7.  Inflammation, Immune Activation, and Antiretroviral Therapy in HIV.

Authors:  Corrilynn O Hileman; Nicholas T Funderburg
Journal:  Curr HIV/AIDS Rep       Date:  2017-06       Impact factor: 5.071

8.  HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways.

Authors:  Rachel P Simmons; Eileen P Scully; Erin E Groden; Kelly B Arnold; J Judy Chang; Kim Lane; Jeff Lifson; Eric Rosenberg; Douglas A Lauffenburger; Marcus Altfeld
Journal:  AIDS       Date:  2013-10-23       Impact factor: 4.177

Review 9.  Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.

Authors:  Babafemi Taiwo; Luis Barcena; Randall Tressler
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

Review 10.  Immune activation and HIV persistence: considerations for novel therapeutic interventions.

Authors:  Hiroyu Hatano
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.